Document Type

Article

Publication Date

9-1-2022

Comments

This article is the author’s final published version in MedComm, Volume 3, Issue 3, September 2022, Article number e145.

The published version is available at https://doi.org/10.1002/mco2.145. Copyright © He et al.

Abstract

Comprehensive understanding of cancer-specific survival differences in gender is critical for cancer prevention and treatment. Based on the Surveillance Epidemiology and End Results database, we included data from the most prevalent cancers (lung, esophageal, liver, pancreatic, stomach, colorectal, kidney, and bladder cancer). Cox proportional hazards regression models were constructed to estimate hazard ratios, simultaneously adjusting for demographic, clinical, and treatment factors. Overall, male patients had a worse cancer-specific survival than female patients. After adjustment for cancer prevalence with 1:1 matching, gender remained a significant factor in cancer-specific survival. Among the included cancer types, female patients showed survival benefit in lung, liver, colorectal, pancreatic, stomach, and esophageal cancer, and male patients showed better survival in bladder cancer. Except for kidney cancer, the gender disparity was consistent between cancer patients with nonmetastatic and metastatic disease. Overall, gender appears to be a significant factor influencing cancer-specific survival, and the prognosis of female patients is better than male patients in most cancers. This work might inspire the development of strategies for gender-specific precision cancer prevention and treatment.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

PubMed ID

35783087

Language

English

Download

Included in

Oncology Commons

Share

COinS